Form 4: Teva Exec Sells Shares After RSU Vesting

Christine Fox, Teva's EVP, Head of U.S. Commercial, sold a portion of her ordinary shares to cover tax obligations following the vesting of restricted share units.

Summary

• Christine Fox, Teva Pharmaceutical Industries Ltd.'s EVP, Head of U.S. Commercial, reported transactions on November 20, 2025.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on August 11, 2025.
• Fox acquired 63,492 ordinary shares through the vesting of restricted share units (RSUs).
• Concurrently, she disposed of 28,229 ordinary shares at a price of $24.7803 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Fox directly beneficially owns 63,647 ordinary shares.
• The RSUs were granted on November 20, 2023, with 63,492 units vesting on November 20, 2024, and another 63,492 vesting on November 20, 2025. Additional units are scheduled to vest on November 20, 2026, and November 20, 2027.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the vesting of restricted share units and a subsequent sale to cover tax obligations, which is a standard and expected event in executive compensation. It does not indicate any significant positive or negative operational or strategic developments for the company.

Positives

• Vesting of 63,492 restricted share units indicates the fulfillment of performance or tenure conditions for the executive.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, suggesting a planned and non-discretionary sale.

Negatives

• The sale of 28,229 ordinary shares by an executive, even for tax purposes, reduces their direct ownership stake in the company.

Future Outlook

The filing indicates future vesting of 63,492 restricted share units on November 20, 2026, and another 63,492 on November 20, 2027, suggesting continued long-term incentive alignment for the executive.

Industry Context

This is a routine insider transaction related to executive compensation and tax obligations, common across all industries for publicly traded companies. It does not provide specific insights into Teva's operational performance or broader pharmaceutical industry trends.

Comparison to Industry Standards

• The use of restricted share units (RSUs) as a component of executive compensation is a standard practice in the pharmaceutical industry and across large corporations globally.
• The adoption of a Rule 10b5-1 trading plan for pre-scheduled sales to cover tax liabilities is also a common and accepted practice for insiders, designed to avoid accusations of trading on material non-public information.

Related Party Transactions

• The transactions involve an executive of the company, which is inherently a related party transaction in the context of compensation and share ownership.

Stakeholder Impact

• Shareholders: Minimal direct impact. The sale is for tax purposes and pre-planned, not indicative of a lack of confidence. The increase in shares outstanding from vesting is minor.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Future vesting of 63,492 restricted share units on November 20, 2026.
• Future vesting of 63,492 restricted share units on November 20, 2027.

Key Dates

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, insider trading, beneficial ownership, restricted share units, RSU vesting, stock sale, executive compensation, Christine Fox, Rule 10b5-1